Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder

Bibliography

• ABRAMS P, CARDOZO L, FALL M et al.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. (2002) 21(2):167-178.
   PubMed Web of Science ®Google Scholar
• ABRAMS P: Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology (2003) 62(Suppl. 2):28-37.
   PubMed Web of Science ®Google Scholar
• ABRAMS P, ARTIBANI W, CARDOZO L et al.: Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol. Urodyn. (2006) 25(3):293.
   PubMed Web of Science ®Google Scholar
• STEWART WF, VAN ROOYEN JB, CUNDIFF GW et al.: Prevalence and burden of overactive bladder in the United States. World J. Urol. (2003) 20(6):327-336.
   PubMed Web of Science ®Google Scholar
• MILSOM I, ABRAMS P, CARDOZO L et al.: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. (2001) 87(9):760-766.
   PubMed Web of Science ®Google Scholar
• DEBRUYNE FM, HEESAKKERS JP: Clinical and socioeconomic relevance of overactive bladder. Urology (2004) 63(3 Suppl. 1):42-44.
   PubMedGoogle Scholar
• HOMMA Y, YAMAGUCHI O, HAYASHI K: An epidemiological survey of overactive bladder symptoms in Japan. BJU Int. (2005) 96(9):1314-1318.
   PubMed Web of Science ®Google Scholar
• ERDEM N, CHU FM: Management of overactive bladder and urge urinary incontinence in the elderly patient. Am. J. Med. (2006) 119(3 Suppl. 1):29-36.
   PubMed Web of Science ®Google Scholar
• TUBARO A, PALLESCHI G: Overactive bladder: epidemiology and social impact. Curr. Opin. Obstet. Gynecol. (2005) 17(5):507-511.
   PubMed Web of Science ®Google Scholar
• ROVNER ES, GOMES CM, TRIGO-ROCHA FE, ARAP S, WEIN AJ: Evaluation and treatment of the overactive bladder. Rev. Hosp. Clin. Fac. Med. Sao Paulo (2002) 57(1):39-48.
   PubMedGoogle Scholar
• LIBERMAN JN, HUNT TL, STEWART WF et al.: Health-related quality of life among adults with symptoms of overactive bladder: results from a US community-based survey. Urology (2001) 57(6):1044-1050.
   PubMed Web of Science ®Google Scholar
• EPSTEIN LB, GOLDBERG RP: The overactive bladder and quality of life. Int. J. Fertil. Womens Med. (2005) 50(1):30-36.
   PubMed Web of Science ®Google Scholar
• MULLINS CD, SUBAK LL: New perspectives on overactive bladder: quality of life impact, medication persistency, and treatment costs. Am. J. Manag. Care (2005) 1(4 Suppl.):S101-S102.
   Google Scholar
• WAGNER TH, HU TW, BENTKOVER J et al.: Health-related consequences of overactive bladder. Am. J. Manag. Care (2002) 8(19 Suppl.):S598-S607.
   PubMed Web of Science ®Google Scholar
• DARKOW T, FONTES CL, WILLIAMSON TE: Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy (2005) 25(4):511-519.
   PubMed Web of Science ®Google Scholar
• HU TW, WAGNER TH: Health-related consequences of overactive bladder: an economic perspective. BJU Int. (2005) 96(Suppl. 1):43-45.
   PubMed Web of Science ®Google Scholar
• WU EQ, BIRNBAUM H, MARYNCHENKO M et al.: Employees with overactive bladder: work loss burden. J. Occup. Environ. Med. (2005) 47(5):439-446.
   PubMed Web of Science ®Google Scholar
• WEIN AJ: Diagnosis and treatment of the overactive bladder. Urology (2003) 62(5 Suppl. 2):20-27.
   PubMedGoogle Scholar
• MADERSBACHER H: Overactive bladder – a practical approach to evaluation and management. J. Med. Liban. (2004) 52(4):220-226.
   PubMedGoogle Scholar
• HO MH, LIN LL, HAESSLER AL, BHATIA NN: Intravesical injection of botulinum toxin for the treatment of overactive bladder. Curr. Opin. Obstet. Gynecol. (2005) 17(5):512-518.
   PubMedGoogle Scholar
• TAKEDA M, OBARA K, MIZUSAWA T et al.: Evidence for β3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J. Pharmacol. Exp. Ther. (1999) 288(3):1367-1373.
   PubMed Web of Science ®Google Scholar
• CARROLL WA, ALTENBACH RJ, BAI H et al.: Synthesis and structure–activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b] quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b] quinolin-8(4H)-one 1,1-dioxide (A-278637), a potent K(ATP) opener that selectively inhibits spontaneous bladder contractions. J. Med. Chem. (2004) 47(12):3163-3179.
   PubMed Web of Science ®Google Scholar
• GU BJ, ISHIZUKA O, IGAWA Y, NISHIZAWA O, ANDERSSON KE: Role of supraspinal tachykinins for micturition in conscious rats with and without bladder outlet obstruction. Naunyn Schmiedebergs Arch. Pharmacol. (2000) 361(5):543-548.
   PubMedGoogle Scholar
• CHU FM, DMOCHOWSKI R: Pathophysiology of overactive bladder. Am. J. Med. (2006) 119(3 Suppl. 1):3-8.
   PubMed Web of Science ®Google Scholar
• STASKIN DR, TE AE: Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. BJU Int. (2006) 97(6):1256-1261.
   PubMedGoogle Scholar
• KELLEHER C, CARDOZO L, KOBASHI K, LUCENTE V: Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. Int. Urogynecol. J. Pelvic Floor Dysfunct. (2006) 17(4):382-388.
   PubMedGoogle Scholar
• PAYNE CK: Solifenacin in overactive bladder syndrome. Drugs (2006) 66(2):175-190.
   PubMed Web of Science ®Google Scholar
• VESICARE US PI: Vesicare US prescribing information. Deerfield (IL): Astellas Pharma Inc.
   Google Scholar
• ROBINSON D, CARDOZO L: Solifenacin in the management of the overactive bladder syndrome. Int. J. Clin. Pract. (2005) 59(10):1229-1236.
   PubMedGoogle Scholar
• OHTAKE A, UKAI M, HATANAKA T et al.: In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur. J. Pharmacol. (2004) 492(2-3):243-250.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI S, IKEDA K, MIYATA K: Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci. (2004) 74(7):843-853.
   PubMed Web of Science ®Google Scholar
• OKI T, SATO S, MIYATA K, YAMADA S: Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. Br. J. Pharmacol. (2005) 145(2):219-227.
   PubMedGoogle Scholar
• KUIPERS ME, KRAUWINKEL WJ, MULDER H, VISSER N: Solifenacin demonstrates high absolute bioavailability in healthy men. Drugs R D (2004) 5(2):73-81.
   PubMedGoogle Scholar
• SMULDERS RA, KRAUWINKEL WJ, SWART PJ, HUANG M: Pharmacokinetics and safety of solifenacin succinate in healthy young men. J. Clin. Pharmacol. (2004) 44(9):1023-1033.
   PubMed Web of Science ®Google Scholar
• MICHEL MC, MINEMATSU T, HASHIMOTO T, DEN HOVEN WV, SWART PJ: In vitro studies on the potential of solifenacin for drug–drug interactions: plasma protein binding and MDR1 transport. Proceedings of the BPS Clinical Pharmacology Section (2004) 59(5):647.
   Google Scholar
• YANAGIHARA T, KAMIYAMA Y, IWATSOBU T et al.: In vitro metabolism of a new anti-muscarinic agent solifenacin succinate in humans. Drug Metab. Rev. (2003) 35(Suppl 2):183.
   Google Scholar
• SMULDERS RA, KUIPERS ME, KRAUWINKEL WJJ: Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or the pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects. Br. J. Clin. Pharmacol. (2006) 62(2):210-217
   Google Scholar
• TAEKEMA-ROELVINK ME, SWART PJ, KUIPERS ME et al.: Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study. Clin. Ther. (2005) 27(9):1403-1410.
   PubMed Web of Science ®Google Scholar
• SMITH N, VAN ZIJTVELD J, SWART P: Co-administration of ketoconazole, a potent CYP3A4 inhibitor, does not affect safety or tolerability of YM905. International Continence Society 32nd Annual Meeting. Heidelberg, Germany (28 – 30 August 2002).
   Google Scholar
• KRAUWINKEL WJ, SMULDERS RA, MULDER H, SWART PJ, TAEKEMA-ROELVINK ME: Effect of age on the pharmacokinetics of solifenacin in men and women. Int. J. Clin. Pharmacol. Ther. (2005) 43(5):227-238.
   PubMed Web of Science ®Google Scholar
• UCHIDA T, KRAUWINKEL WJ, MULDER H, SMULDERS RA: Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial. Br. J. Clin. Pharmacol. (2004) 58(1):4-7.
   PubMed Web of Science ®Google Scholar
• SMULDERS R, SMITH N, KRAUWINKEL W, AL E: The safety and tolerability of solifenacin succinate in patients with renal disease. Gerontological Society of America 56th Annual Scientific Meeting. San Diego (CA) USA (21 – 25 November 2003).
   Google Scholar
• KUIPERS M, SMULDERS R, KRAUWINKEL W: The safety, tolerability and pharmacokinetics of solifenacin succinate in patients with hepatic impairment. International Continence Society 33rd Annual Meeting. Florence, Italy (5 – 9 October 2003).
   Google Scholar
• CHAPPLE CR, ARANO P, BOSCH JL et al.: Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled Phase II dose-finding study. BJU Int. (2004) 93(1):71-77.
   PubMed Web of Science ®Google Scholar
• SMITH N, GRIMES I, RIDGE S, TEMPEL D, UCHIDA T: YM905 is effective and safe as treatment of overactive bladder in women and men: results from Phase II study. International Continence Society 32nd Annual Meeting (2002) Heidelberg, Germany (28 – 30 August 2002).
   Google Scholar
• CHAPPLE CR, RECHBERGER T, AL-SHUKRI S et al.: Randomized, double-blind placebo- and tolterodine-controlled trial of the once daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. (2004) 93(3):303-310.
   PubMed Web of Science ®Google Scholar
• CARDOZO L, LISEC M, MILLARD R et al.: Randomized, double-blind placebo-controlled trial of once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J. Urol. (2004) 172:1919-1924.
   PubMed Web of Science ®Google Scholar
• GITTELMAN M: Solifenacin succinate 10 mg once daily significantly improves symptoms of overactive bladder. AUA Western Congress 78th Meeting (2003).
   Google Scholar
• ABRAMS P, SWIFT S: Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur. Urol. (2005) 48(3):483-487.
   PubMed Web of Science ®Google Scholar
• HAAB F, CARDOZO L, CHAPPLE C, RIDDER AM: Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur. Urol. (2005) 47(3):376-384.
   PubMed Web of Science ®Google Scholar
• STASKIN DR, MACDIARMID SA: Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. Am. J. Med. (2006) 119(3 Suppl. 1):9-15.
   PubMed Web of Science ®Google Scholar
• YU YF, NICHOL MB, YU AP, AHN J: Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health (2005) 8(4):495-505.
   PubMed Web of Science ®Google Scholar
• CHAPPLE C, KHULLAR V, GABRIEL Z, DOOLEY JA: The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur. Urol. (2005) 48(1):5-26.
   PubMed Web of Science ®Google Scholar
• HAAB F, STEWART L, DWYER P: Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur. Urol. (2004) 45(4):420-429; discussion 429.
   PubMed Web of Science ®Google Scholar
• ABRAMS P, CARDOZO L, CHAPPLE C et al.: Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int. J. Urol. (2006) 13(6):692-698.
   PubMed Web of Science ®Google Scholar
• NITTI VW, DMOCHOWSKI R, APPELL RA et al.: Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int. (2006) 97(6):1262-1266.
   PubMed Web of Science ®Google Scholar
• ZINNER N, GITTELMAN M, HARRIS R et al.: Trospium chloride improves overactive bladder symptoms: a multicenter Phase III trial. J. Urol. (2004) 171(6 Pt 1):2311-2315.
   PubMed Web of Science ®Google Scholar
• SCHEIFE R, TAKEDA M: CNS safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin. Ther. (2005) 27(2):144-153.
   PubMed Web of Science ®Google Scholar
• KOPELMAN MD: The cholinergic neurotransmitter system in human memory and dementia: a review. Q J Exp. Psychol. A. (1986) 38(4):535-573.
   PubMedGoogle Scholar
• KAY GG, ABOU-DONIA MB, MESSER WS Jr et al.: Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J. Am. Geriatr. Soc. (2005) 53(12):2195-2201.
   PubMed Web of Science ®Google Scholar
• STASKIN DR: Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging (2005) 22(12):1013-1028.
   PubMed Web of Science ®Google Scholar
• WAGG A, WYNDAELE JJ, SIEBER P: Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am. J. Geriatr. Pharmacother. (2006) 4(1):14-24.
   PubMedGoogle Scholar
• HASHIM H, ABRAMS P: Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs (2004) 64(15):1643-1656.
   PubMed Web of Science ®Google Scholar
• KELLEHER CJ, CARDOZO L, CHAPPLE CR, HAAB F, RIDDER AM: Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. (2005) 95(1):81-85.
   PubMed Web of Science ®Google Scholar
• DONOVAN J, BADIA X, CORCOS J, AL E: Symptom and quality of life assessment. In: Incontinence. Abrams P et al. (Eds). U.K. Health Publication Ltd, Plymouth (2002):267-316.
   Google Scholar
• KELLEHER CJ, CARDOZO LD, KHULLAR V, SALVATORE S: A new questionnaire to assess the quality of life of urinary incontinent women. BJOG (1997) 104(12):1374-1379.
   Web of Science ®Google Scholar
• STASKIN DR, MACDIARMID SA: Pharmacologic management of overactive bladder: practical options for the primary care physician. Am. J. Med. (2006) 119(3 Suppl. 1):24-28.
   PubMed Web of Science ®Google Scholar
• BALKRISHNAN R, BHOSLE MJ, CAMACHO FT, ANDERSON RT: Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. J. Urol. (2006) 175(3 Pt 1):1067-1071; discussion 1071-1072.
   PubMed Web of Science ®Google Scholar
• KELLEHER CJ, CARDOZO LD, KHULLAR V, SALVATORE S: A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br. J. Obstet. Gynaecol. (1997) 104(9):988-993.
   PubMedGoogle Scholar
• CHAPPLE C, CARDOZO L, STEERS W, GOVIER F: Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int. J. Clin. Prac. (2006) 60(8):959-966.
   PubMed Web of Science ®Google Scholar
• NILVEBRANT L, ANDERSSON KE, GILLBERG PG, STAHL M, SPARF B: Tolterodine – a new bladder-selective antimuscarinic agent. Eur. J. Pharmacol. (1997) 327(2-3):195-207.
   PubMed Web of Science ®Google Scholar
• STAHL MM, EKSTROM B, SPARF B, MATTIASSON A, ANDERSSON KE: Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol. Urodyn (1995) 14(6):647-655.
   PubMed Web of Science ®Google Scholar
• KREDER K, MAYNE C, JONAS U: Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur. Urol. (2002) 41(6):588-595.
   PubMed Web of Science ®Google Scholar
• CHAPPLE CR, MARTINEZ-GARCIA R, SELVAGGI L et al.: A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR Trial. Eur. Urol. (2005) 48(3):464-470.
   PubMed Web of Science ®Google Scholar
• CHAPPLE C, BALLANGER P, HATZICHRISTOU D et al.: Improvements in bladder condition in OAB perceived and experienced by patients in a solifenacin versus tolterodine multinational trial (STAR study). International Continence Society 35th Annual Meeting. Montreal, Canada (28 August – 2 September 2005)
   Google Scholar
• CHAPPLE C, FIALA R, GORILOVSKY L et al.: The STAR study: analysis of symptom severity and treatment response in overactive bladder. European Association of Urology. Paris, France (5 – 8 April 2006).
   Google Scholar
• ZINNER N, TUTTLE J, MARKS L: Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J. Urol. (2005) 23(4):248-252.
   PubMed Web of Science ®Google Scholar
• HOMMA Y, PAICK JS, LEE JG, KAWABE K: Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int (2003) 92(7):741-747.
   PubMed Web of Science ®Google Scholar
• MADERSBACHER H, STOHRER M, RICHTER R et al.: Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br. J. Urol. (1995) 75(4):452-456.
   PubMedGoogle Scholar
• SCHRODER S, JETTER A, ZAIGLER M et al.: Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration. Int. J. Clin. Pharmacol. Ther. (2004) 42(10):543-549.
   PubMed Web of Science ®Google Scholar
• MADERSBACHER H, HALASKA M, VOIGT R, ALLOUSSI S, HOFNER K: A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int. (1999) 84(6):646-651.
   PubMed Web of Science ®Google Scholar
• JUNEMANN KP, HALASKA M, RITTSTEIN T et al.: Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur. Urol. (2005) 48(3):478-482.
   PubMed Web of Science ®Google Scholar
• ABRAMS P, CARDOZO L, FALL M et al.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am. J. Obstet. Gynecol. (2002) 187(1):116-126.
   PubMed Web of Science ®Google Scholar
• NIXON A, COLMAN S, SABOUNJIAN L et al.: A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J. Urol. (2005) 174(2):604-607.
   PubMed Web of Science ®Google Scholar